5-HT(1A) receptor activation by the very-high-efficacy, selective
5-HT(1A) receptor agonist
F 13640 [(3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-([(5-methyl-pyridin-2-ylmethyl)-amino]-methyl)piperidin-1-yl]-methanone] was recently discovered to constitute a novel central mechanism of broad-spectrum
analgesia that, remarkably, grows rather than decays with chronicity. However, in rodents not exposed to nociception,
F 13640 induces its
analgesic effect only after having initially induced
hyperalgesia. Numerical simulations implementing a signal transduction theory here show that the progressive increase in the intensity of nociceptive stimulation which
F 13640 presumably mimics should eventually produce a large
analgesic effect without initially causing marked
pain. In vivo studies examined the effects of progressively increasing doses of
F 13640 on the threshold of mechanically induced vocalization and, also, on the
5-HT syndrome in rats. The infusion of increasing (0.04-0.63 mg/rat/day) doses of
F 13640 over a 5-week period induced a large
analgesia preceded by a hyperalgesic effect that was small and comparable to that induced by initial exposure to a low, 0.04 mg/rat/day dose. Furthermore, increasing the dose of
F 13640 induced tachyphylaxis to the
5-HT syndrome. Producing the mirror opposite of
morphine's neuroadaptive actions,
F 13640 causes an
analgesia that becomes more powerful with chronic administration, and this at the expense of the initial
hyperalgesia which it may also produce.